Sees 2023 Dojolvi revenue $65M-$75M. Sees 2023 total Crysvita revenue $325M-$340M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
- Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Ultragenyx assumed with a Buy at H.C. Wainwright
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Present at Piper Sandler Healthcare Conference